Learning from past experience will benefit PHARMAC, the Pharmaceutical Management Agency of New Zealand, well as it takes a greater role in purchasing hospital medicines, says chief executive Matthew Brougham in the agency’s 2010 Annual Review released yesterday.
The Government this year gave PHARMAC an expanded role in purchasing hospital medicines. PHARMAC has begun this task with a series of meetings with senior District Health Board (DHB) executives, clinical leaders and pharmacy staff to gather information about how each DHB deals with hospital purchasing. PHARMAC has visited 21 DHB hospitals.
Mr Brougham says the hospital project is a long-term one, and building relationships and trust will be an important part of ensuring its success and “it’s likely that over time there will be savings, but that’s not the critical issue at the outset.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze